JP2021533080A5 - - Google Patents

Info

Publication number
JP2021533080A5
JP2021533080A5 JP2020555115A JP2020555115A JP2021533080A5 JP 2021533080 A5 JP2021533080 A5 JP 2021533080A5 JP 2020555115 A JP2020555115 A JP 2020555115A JP 2020555115 A JP2020555115 A JP 2020555115A JP 2021533080 A5 JP2021533080 A5 JP 2021533080A5
Authority
JP
Japan
Prior art keywords
tranilast
powder
ray diffraction
salt
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020555115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533080A (ja
JP7372259B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/071881 external-priority patent/WO2020035546A1/en
Publication of JP2021533080A publication Critical patent/JP2021533080A/ja
Publication of JP2021533080A5 publication Critical patent/JP2021533080A5/ja
Application granted granted Critical
Publication of JP7372259B2 publication Critical patent/JP7372259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555115A 2018-08-14 2019-08-14 結晶トラニラスト塩およびこれらの医薬的な使用 Active JP7372259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718563P 2018-08-14 2018-08-14
US62/718,563 2018-08-14
PCT/EP2019/071881 WO2020035546A1 (en) 2018-08-14 2019-08-14 Crystalline tranilast salts and their pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2021533080A JP2021533080A (ja) 2021-12-02
JP2021533080A5 true JP2021533080A5 (cg-RX-API-DMAC7.html) 2022-10-28
JP7372259B2 JP7372259B2 (ja) 2023-10-31

Family

ID=67997566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555115A Active JP7372259B2 (ja) 2018-08-14 2019-08-14 結晶トラニラスト塩およびこれらの医薬的な使用

Country Status (5)

Country Link
US (2) US11078155B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837238B1 (cg-RX-API-DMAC7.html)
JP (1) JP7372259B2 (cg-RX-API-DMAC7.html)
CN (1) CN112236413A (cg-RX-API-DMAC7.html)
WO (1) WO2020035546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078155B2 (en) * 2018-08-14 2021-08-03 Nuformix Technologies Limited Crystalline tranilast salts and their pharmaceutical use
US20230146308A1 (en) * 2020-03-19 2023-05-11 Softhale Nv Method for the treatment nlrp3-associated diseases
AU2022443590A1 (en) 2022-02-28 2024-10-17 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5848545B2 (ja) * 1974-04-18 1983-10-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ
US4587356A (en) * 1981-09-01 1986-05-06 Kissei Pharmaceutical Co., Ltd. Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives
EP0189861A3 (en) * 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
ES8606846A1 (es) * 1985-07-11 1986-05-16 Uriach & Cia Sa J Procedimiento de obtencion del acido 2-((3-3,4-dimetoxifenil-1-oxo-2-propenil)amino)benzoico
JPH07116029B2 (ja) 1989-04-04 1995-12-13 キッセイ薬品工業株式会社 トラニラスト水溶液製剤
JP2001187728A (ja) * 1999-12-28 2001-07-10 Lion Corp 眼科用組成物
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP5477996B2 (ja) * 2003-09-30 2014-04-23 ロート製薬株式会社 透明包装体入りトラニラスト含有医薬製剤
JP2006306765A (ja) * 2005-04-27 2006-11-09 Nippon Tenganyaku Kenkyusho:Kk トラニラスト水性点眼液
JPWO2007046544A1 (ja) 2005-10-21 2009-04-30 株式会社 メドレックス カルボキシル基を有する肥満細胞脱顆粒抑制剤と有機アミンとの塩を含有する外用剤
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CN104379130B (zh) 2012-03-30 2018-01-02 诺弗米克斯有限公司 曲尼司特组合物和共结晶体
KR101878370B1 (ko) 2016-12-30 2018-07-13 한국과학기술원 진동 감쇠 장치
US11078155B2 (en) * 2018-08-14 2021-08-03 Nuformix Technologies Limited Crystalline tranilast salts and their pharmaceutical use

Similar Documents

Publication Publication Date Title
JP2013237682A5 (cg-RX-API-DMAC7.html)
JP2022502500A5 (cg-RX-API-DMAC7.html)
IL274488B2 (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
JP2018531963A5 (cg-RX-API-DMAC7.html)
JP2014524442A5 (cg-RX-API-DMAC7.html)
JP2018035160A5 (cg-RX-API-DMAC7.html)
HRP20160208T4 (hr) Polimorfi dasatiniba i postupak za njihovu pripremu
JP2009534373A5 (cg-RX-API-DMAC7.html)
JP2020512350A5 (cg-RX-API-DMAC7.html)
JP2015500331A5 (cg-RX-API-DMAC7.html)
RU2015106137A (ru) Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
RU2009136593A (ru) Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших
JP2016503010A5 (cg-RX-API-DMAC7.html)
CN115515938A (zh) FXIa抑制剂化合物的盐及其制备方法和医药用途
JP2020536893A5 (cg-RX-API-DMAC7.html)
JP2013503134A5 (cg-RX-API-DMAC7.html)
JP2014530818A5 (cg-RX-API-DMAC7.html)
JP2015522037A5 (cg-RX-API-DMAC7.html)
PT1296951E (pt) 5-cloro-3-(4-metanossulfonilfenil)-6'-metil-[2,3'] bipiridinilo na forma cristalina pura e processo para sua síntese
JP2015516425A5 (cg-RX-API-DMAC7.html)
JP2016537326A5 (cg-RX-API-DMAC7.html)
JP2016510768A5 (cg-RX-API-DMAC7.html)
HRP20251507T1 (hr) Kristalna fumaratna sol od (s)-[3,4-difluoro-2-(2-fluoro-4-jodofenilamino)fenil] [3-hidroksi-3-(piperidin-2-il)azetidin-1-il]metanona
JP2023027066A5 (cg-RX-API-DMAC7.html)
JP2005529084A5 (cg-RX-API-DMAC7.html)